News
ATRA
5.24
0.00%
0.00
ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
PR Newswire · 10h ago
Atara Biotherapeutics Faces Securities Lawsuit After FDA Setbacks and Sharp Stock Declines Tied to Tabelecleucel
TipRanks · 12h ago
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit
PR Newswire · 2d ago
Weekly Report: what happened at ATRA last week (0406-0410)?
Weekly Report · 3d ago
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 6d ago
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 04/07 16:00
Weekly Report: what happened at ATRA last week (0330-0403)?
Weekly Report · 04/06 10:20
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit
PR Newswire · 04/04 05:16
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR Newswire · 04/03 19:24
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Barchart · 04/02 12:46
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA
PR Newswire · 04/01 13:00
Deadline Approaching: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Barchart · 04/01 11:00
Law Offices of Frank R. Cruz Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
Barchart · 03/31 11:08
Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Atara Biotherapeutics (ATRA) and Rezolute (RZLT)
TipRanks · 03/30 13:10
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
Barchart · 03/30 11:30
Weekly Report: what happened at ATRA last week (0323-0327)?
Weekly Report · 03/30 10:20
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit
PR Newswire · 03/29 22:12
Atara Biotherapeutics Faces Federal Securities Lawsuit Over Alleged Misstatements About Drug Approval Prospects
TipRanks · 03/27 18:11
Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action
Barchart · 03/27 13:51
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Barchart · 03/26 12:09
More
Webull provides a variety of real-time ATRA stock news. You can receive the latest news about Atara Biotherape through multiple platforms. This information may help you make smarter investment decisions.
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.